Showing 1,501 - 1,520 results of 16,418 for search '"Therapy"', query time: 0.15s Refine Results
  1. 1501

    Effects of levothyroxine therapy on bone and mineral metabolism in hypothyroidism: a systematic review and meta-analysis by Xiaotao Li, Taotao Zhang, Hongling Zhang, Shanshan Liu, Limin Tian

    Published 2025-01-01
    “…Conclusion This systematic review and meta-analysis demonstrated that there is a slight adverse effect of LT4 replacement therapy on bone and mineral metabolism in patients with OH, while no observed effect was found in SCH patients.…”
    Get full text
    Article
  2. 1502

    Family participatory clown therapy in venipuncture in hospitalized children: A non-randomized controlled trial. by Tianyu Chen, Qiying Chen, Zhenhua Lin, Jingfang Ye

    Published 2024-01-01
    “…<h4>Objective</h4>To explore the effectiveness of family participatory clown therapy in venipuncture in hospitalized children.<h4>Methods</h4>We recruited 104 children aged 3 to 6 years for a non-randomized controlled trial from March to December 2022. …”
    Get full text
    Article
  3. 1503

    Safety of Sofosbuvir and Ribavirin Combination Therapy in a Patient Who Developed Anemia due to Ribavirin by Hirokazu Suii, Itaru Ozeki, Ryoji Tatsumi, Masakatsu Yamaguchi, Mutsuumi Kimura, Tomohiro Arakawa, Tomoaki Nakajima, Yasuaki Kuwata, Takumi Ohmura, Shuhei Hige, Yoshiyasu Karino, Joji Toyota

    Published 2017-01-01
    “…In 2014, sofosbuvir (SOF) was approved for the treatment of chronic HCV genotype 2 in Japan. SOF/RBV therapy is more effective against genotype 2 than IFN/RBV therapy. …”
    Get full text
    Article
  4. 1504

    Anti-TNF-α Therapy Suppresses Proinflammatory Activities of Mucosal Neutrophils in Inflammatory Bowel Disease by Cui Zhang, Weigang Shu, Guangxi Zhou, Jian Lin, Feifei Chu, Huili Wu, Zhanju Liu

    Published 2018-01-01
    “…Herein, we found that anti-TNF-α therapy significantly downregulated infiltration of neutrophils in inflamed mucosa of IBD patients. …”
    Get full text
    Article
  5. 1505
  6. 1506

    Adaptive Immunity in Ankylosing Spondylitis: Phenotype and Functional Alterations of T-Cells before and during Infliximab Therapy by Balázs Szalay, Gergő Mészáros, Áron Cseh, Lilla Ács, Magdolna Deák, László Kovács, Barna Vásárhelyi, Attila Balog

    Published 2012-01-01
    “…The prevalence of Th2 and Th17 cells responsible for the regulation of adaptive immunity was higher in AS than in 9 healthy controls. Although IFX therapy improved patients' condition, immune phenotype did not normalize. …”
    Get full text
    Article
  7. 1507
  8. 1508

    The Management of Iron Chelation Therapy: Preliminary Data from a National Registry of Thalassaemic Patients by Adriana Ceci, Laura Mangiarini, Mariagrazia Felisi, Franco Bartoloni, Angela Ciancio, Marcello Capra, Domenico D'Ascola, Paolo Cianciulli, Aldo Filosa

    Published 2011-01-01
    “…A new initiative was promoted by the Italian Ministry of Health, establishing a Registry for thalassaemic patients to serve as a tool for the development of cost-effective diagnostic and therapeutic approaches and for the definition of guidelines supporting the most appropriate management of the iron-chelating therapy and a correct use of the available iron-chelating agents. …”
    Get full text
    Article
  9. 1509
  10. 1510

    Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China by Chengguang Hu, Guosheng Yuan, Junwei Liu, Huaping Huang, Yanyu Ren, Yinping Li, Xuefu Chen, Wei Li, Tao Wu, Hong Deng, Yanzhong Peng, Yong-Yuan Zhang, Yuanping Zhou

    Published 2018-01-01
    “…There is scarcity of data in literature regarding the treatment response to sofosbuvir- (SOF-) based therapies in Chinese patients with chronic Hepatitis C Virus (HCV) infection. …”
    Get full text
    Article
  11. 1511

    Postprogression therapy and confounding for the estimated treatment effect on overall survival in phase III oncology trials by Pavlos Msaouel, Ramez Kouzy, Joseph Abi Jaoude, Ethan B Ludmir, Alexander D Sherry, Timothy A Lin, Esther J Beck, Avital M Miller, Adina H Passy, Gabrielle S Kupferman, Eugene J Koay, Clifton David Fuller, Charles R Thomas, Zachary R McCaw

    Published 2024-07-01
    “…Objective Estimations of the treatment effect on overall survival (OS) may be influenced by post-progression therapies (PPTs). It is unclear how often OS analyses account for PPT effects. …”
    Get full text
    Article
  12. 1512

    Metastatic melanoma: An integrated analysis to identify critical regulators associated with prognosis, pathogenesis and targeted therapies. by Zeinab Chaharlashkar, Yousof Saeedi Honar, Meghdad Abdollahpour-Alitappeh, Sepideh Parvizpour, Abolfazl Barzegar, Effat Alizadeh

    Published 2025-01-01
    “…The items recognized in the current study can be used as potential biomarkers for diagnostic, predictive, and might helpful to develop targeted combined therapies.…”
    Get full text
    Article
  13. 1513
  14. 1514
  15. 1515
  16. 1516

    Activins and Follistatin in Chronic Hepatitis C and Its Treatment with Pegylated-Interferon-α Based Therapy by Bassem Refaat, Ahmed Mohamed Ashshi, Adel Galal El-Shemi, Esam Azhar

    Published 2015-01-01
    “…Pegylated-interferon-α based therapy for the treatment of chronic hepatitis C (CHC) is considered suboptimal as not all patients respond to the treatment and it is associated with several side effects that could lead to dose reduction and/or termination of therapy. …”
    Get full text
    Article
  17. 1517
  18. 1518
  19. 1519
  20. 1520